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Chronic kidney disease (CKD) is a public health priority.
The unadjusted mortality rate of end-stage renal disease
(ESRD) is 29% at 2 years and 52% at 5 years. ESRD is
associated with cardiovascular (CV) morbidity and morta-
lity 2 to 10 times that of a population with normal renal
function. Heart disease is the leading cause of mortality in
patients on hemodialysis (HD) (42% of total mortality) (1).See page 528Despite these observations few pharmacological treatments
are evidence based because CKD patients on HD are
usually excluded from CV prevention trials. Two trials
including patients with ESRD on HD showed that statins
had no effect (2,3). Aside from 2 positive studies among
patients with ESRD on HD with heart failure and impaired
left ventricular ejection fraction (stage III/IV) in which
a beta-blocker (4) or a combination of an angiotensin-
converting enzyme inhibitor (ACE-I) with an angiotensin
II receptor blocker (ARB) (5) was used, FOSIDIAL
(the Fosinopril in Dialysis study), which was the largest
(n ¼ 397) CV event trial using an antihypertensive agent
that included patients with ESRD on HD with left ven-
tricular hypertrophy, showed that an ACE-I did not achi-
eve statistical signiﬁcance (6). However, a meta-analysis
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drugs as a whole may improve CV outcomes in patients
with ESRD on HD (7).
In patients with heart failure without severe CKD on
an ACE-I or ARB and/or a beta-blocker, the mineralo-
corticoid receptor antagonists (MRAs) spironolactone and
eplerenone have shown a reduction in CV events (8–10).
The beneﬁcial effects of MRAs may involve cardiovascular
remodeling, including collagen turnover (11), as well as
effects on oxidative stress and endothelial and immune
functions (12). Moreover, recent experimental data suggest
that aldosterone may be involved in vascular calciﬁcation,
a prominent feature of vascular aging and CV morbidity in
patients with CKD (13). MRAs have also been shown to
reduce mesangial ﬁbrosis, to prevent podocyte damage, and
to reduce albuminuria (14). A randomized controlled trial
conducted in the early stages of CKD showed that adding
spironolactone to an ACE-I or ARB reduced left ventricular
mass and arterial stiffness, which are independent predictors
of CV events in patients with ESRD (15).
Most clinicians are, however, reluctant to use MRAs in
patients with chronic heart failure, especially in those with
CKD, because of the risk of hyperkalemia. MRAs are
currently contraindicated in patients with an estimated
glomerular ﬁltration rate <30 ml/min/1.73 m2, including
patients on HD. However, recent clinical studies have
demonstrated the safety (especially in regard to hyper-
kalemia) of MRAs in ESRD patients on HD (16). Several
studies also suggest a cardiovascular protective effect while
assessing surrogates such as intima-medial thickness, left
ventricular mass (16), or calciﬁcations (17).
In this issue of the Journal, Matsumoto et al. (18) report
the results of the ﬁrst open-label, randomized trial evaluating
CV and cerebrovascular events in patients with ESRD on
HD (DOHAS [Dialysis Outcomes Heart Failure Aldactone
Study]) comparing the MRA spironolactone (25 mg/day) to
usual care in 309 oligoanuric patients followed up for 3 years.
Strikingly, both the primary and secondary outcomes were
signiﬁcantly reduced. The composite of death from CV and
cerebrovascular events or hospitalization for CV and cere-
brovascular events (primary outcome) was 5.7% (n ¼ 9) in
the treatment group and 12.5% (n ¼ 19) of patients in the
control group, with a hazard ratio (HR) for treatment of
0.404 (95% conﬁdence interval [CI]: 0.202 to 0.809; p ¼
0.017), while death from all causes (secondary outcome) was
6.4% (n ¼ 10) versus 19.7% (n ¼ 30) (HR: 0.355; 95% CI:
0.191 to 0.662; p ¼ 0.002). Three patients (1.9%) dis-
continued spironolactone treatment because of serious
hyperkalemia.
Matsumoto et al. should be congratulated for addressing
the neglected issue of CV events in HD patients and for
incorporating an MRA as a potential therapy in these high-
risk patients. As acknowledged by the authors, DOHAS is
not the deﬁnitive pivotal trial to change clinical practice. They
rightly state that: “First, this study was not blinded. Further,
a placebo was not administered to the control group.
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538Additionally, the interaction tests were underpowered, and
the number of endpoints was small.” Moreover, owing to the
low recruitment rate due to participation refusal (only 309
patients were included vs. the scheduled sample size of 600
patients required to demonstrate a 40% reduction of all-cause
death for a 2-sided alpha level of 0.05, with 80% power), the
external validity of this study will require further conﬁrmation.
The applicability of the results to patients onHDwith residual
diuresis is also uncertain because only oligoanuric patients were
studied. The results are, however, sufﬁciently provocative to
encourage further large-scale, multicenter, randomized,
double-blind, placebo-controlled trials necessary to provide
a deﬁnitive answer as to the role of MRAs in patients with
ESRD on HD. Fortunately, such a trial is underway.
ALCHEMIST (ALdosterone Antagonist Chronic HEMo-
dialysis Interventional Survival Trial; NCT01848639) is
underway and plans to recruit 825 patients with the primary
endpoint of the time to onset of the ﬁrst incident (nonfatal
myocardial infarction or hospitalization for heart failure or
nonfatal stroke or CV death). Thus, the results of DOHAS
and ALCHEMIST hold the promise of a reduction in CV
events in these high-risk patients with ESRD on HD.
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